{"title":"A Review of the Role of Antipsychotics as an Augmentation Agentor Treatment Option for Patients with Treatment Resistant UnipolarDepression","authors":"Anish S. Shah","doi":"10.4172/1522-4821.1000198","DOIUrl":null,"url":null,"abstract":"Background: Patients with unipolar depression present a unique challenge for physicians who are considering therapeutic drug treatment. Physicians have historically treated patients who present symptoms of unipolar depression with SSRIs or other medications that are commonly prescribed to patients with non-unipolar depression. Many of these medications are ineffective for patients suffering from unipolar disorder. Recently, an exciting new treatment approach for the depressive symptoms related to unipolar disorder has emerged in the form of secondgeneration atypical antipsychotics. A wealth of empirical support for treating treatment-resistant bipolar depression is becoming increasingly available, but much less is understood regarding the efficacy of atypical psychotics in treating unipolar depression. Methods: An electronic literature review was conducted through PubMed, PsycINFO, the Cochrane Library, Web of Science, and Embase using the following search phrases: depression, unipolar depression, antipsychotics, second-generation antipsychotics, atypical antipsychotics, and depression treatment. There were no restrictions on publication year, type, or language. Meta-analyses and randomized clinical trials (RCTs) were considered. A sensitivity analysis was performed by excluding studies with small sample sizes and a high placebo effect. Discussion: Preliminary evidence for this treatment approach is promising, although additional clinical trials which more clearly elucidate the role of second-generation atypical antipsychotics in treating unipolar depressive symptoms may be warranted. Accordingly, this article discusses the second-generation atypical antipsychotics that have, to date, received empirical support for use in treating patients with unipolar disorder. Proposed mechanisms of action are discussed and current FDA approvals as well as approval status in different countries for usage are reviewed. Indications for future research are also proposed.","PeriodicalId":358022,"journal":{"name":"International Journal of Emergency Mental Health and Human Resilience","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Emergency Mental Health and Human Resilience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/1522-4821.1000198","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Patients with unipolar depression present a unique challenge for physicians who are considering therapeutic drug treatment. Physicians have historically treated patients who present symptoms of unipolar depression with SSRIs or other medications that are commonly prescribed to patients with non-unipolar depression. Many of these medications are ineffective for patients suffering from unipolar disorder. Recently, an exciting new treatment approach for the depressive symptoms related to unipolar disorder has emerged in the form of secondgeneration atypical antipsychotics. A wealth of empirical support for treating treatment-resistant bipolar depression is becoming increasingly available, but much less is understood regarding the efficacy of atypical psychotics in treating unipolar depression. Methods: An electronic literature review was conducted through PubMed, PsycINFO, the Cochrane Library, Web of Science, and Embase using the following search phrases: depression, unipolar depression, antipsychotics, second-generation antipsychotics, atypical antipsychotics, and depression treatment. There were no restrictions on publication year, type, or language. Meta-analyses and randomized clinical trials (RCTs) were considered. A sensitivity analysis was performed by excluding studies with small sample sizes and a high placebo effect. Discussion: Preliminary evidence for this treatment approach is promising, although additional clinical trials which more clearly elucidate the role of second-generation atypical antipsychotics in treating unipolar depressive symptoms may be warranted. Accordingly, this article discusses the second-generation atypical antipsychotics that have, to date, received empirical support for use in treating patients with unipolar disorder. Proposed mechanisms of action are discussed and current FDA approvals as well as approval status in different countries for usage are reviewed. Indications for future research are also proposed.
背景:单极抑郁症患者对正在考虑药物治疗的医生提出了一个独特的挑战。医生历来用ssri类药物或其他非单极抑郁症患者常用的药物治疗有单极抑郁症症状的患者。许多这些药物对患有单极障碍的患者无效。最近,一种令人兴奋的新治疗方法出现在第二代非典型抗精神病药的形式中,用于治疗与单极障碍相关的抑郁症状。治疗难治性双相抑郁症的经验支持越来越多,但对非典型精神病治疗单相抑郁症的疗效了解甚少。方法:通过PubMed、PsycINFO、Cochrane图书馆、Web of Science和Embase进行电子文献综述,检索词为:抑郁症、单极抑郁症、抗精神病药物、第二代抗精神病药物、非典型抗精神病药物和抑郁症治疗。对出版年份、类型或语言没有限制。我们考虑了meta分析和随机临床试验(rct)。通过排除小样本量和高安慰剂效应的研究进行敏感性分析。讨论:这种治疗方法的初步证据是有希望的,尽管可能需要更多的临床试验来更清楚地阐明第二代非典型抗精神病药物在治疗单相抑郁症状中的作用。因此,本文讨论了第二代非典型抗精神病药物,迄今为止,在治疗单极障碍患者中得到了经验支持。讨论了拟议的作用机制,并审查了目前FDA批准以及不同国家使用的批准状态。并提出了未来研究的适应症。